Compugen Ltd. (CGEN)
NASDAQ (CM) NASDAQ (CM) Primary 
TASE Summary
Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
Compugen Ltd. ( CGEN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Yvonne Naughton - Head of Investor Relations & Corporate Communications Eran Ophir - CEO & Director David Silberman - Chief Financial Officer Michelle Mahler - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Swayampakula Ramakanth - H.C.
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.01 per share a year ago.
Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients
Compugen is advancing its anti-PVRIG antibody COM701 in phase 1/2 as a maintenance therapy for relapsed platinum-sensitive ovarian cancer patients, with interim data expected in 2H 2026. Positive proof-of-concept in platinum-resistant ovarian cancer and strong partnerships with AstraZeneca and Gilead provide multiple value-creation opportunities and financial stability. Upcoming catalysts include ESMO 2025 data releases for COM701 and AstraZeneca-partnered rilvegostomig in solid tumors, offering potential stock-moving events.
Compugen Ltd. (CGEN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Compugen Ltd. ever had a stock split?
Compugen Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Eran Ophir CEO | NASDAQ (CM) Exchange | M25722105 CUSIP |
| IL Country | 74 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Compugen Ltd. operates as a clinical-stage therapeutic discovery and development company, based in Holon, Israel, with active research and development efforts across Israel, the United States, and Europe. Specializing in the field of immuno-oncology, Compugen focuses on the research, development, and commercialization of novel therapeutic and product candidates. Leveraging cutting-edge technologies, the company dedicates its efforts to addressing various cancers through a range of promising therapeutic antibodies. Compugen has established multiple collaboration agreements with leading pharmaceutical companies and research institutions including Bayer Pharma AG, Bristol-Myers Squibb, and Johns Hopkins School of Medicine, highlighting its significant role in advancing immuno-oncology therapeutics towards commercialization. Founded in 1993, Compugen stands at the forefront of immunotherapy research aiming to bring innovative treatments to patients worldwide.
Products and Services
COM701: An anti-PVRIG antibody, currently in Phase I clinical study for treating solid tumors. COM701 aims to modulate the immune system response against tumor cells, marking a significant step in immuno-oncology.
COM902: A therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study. Focused on advanced malignancies, COM902 is tested through sequential dose escalations seeking to enhance immune cell activity against cancers.
Bapotulimab: Targets ILDR2 and is in Phase I clinical study for patients with naïve head and neck squamous cell carcinoma. This therapeutic antibody is another innovative approach to stimulate the immune system's ability to fight cancer.
Rilvegostomig: A novel anti-TIGIT/PD-1 bispecific antibody in Phase II clinical study, targeting patients with advanced or metastatic non-small cell lung cancer. Rilvegostomig represents a dual-focused immuno-oncology strategy, blocking two critical immune-inhibitory pathways.
Early-stage Immuno-oncology Programs: Include a range of projects focused to address various mechanisms of immune resistance. These programs are designed to explore newer therapeutics that could overcome challenges faced by current treatments.
COM503: An antibody that blocks the interaction between IL-18 binding protein and IL-18, signifying a high affinity antibody approach to modulate immune responses against cancerous cells.
Contact Information
